(Reuters) -Medical equipment maker Hologic lowered its fiscal 2025 profit forecast, citing uncertainty around the tariffs imposed by U.S. President Donald Trump’s administration, sending the company’s shares down 3% after the bell on Thursday.
The Marlborough, Massachusetts-based company makes test kits, diagnostic products and cancer screening devices.
The company is lowering its adjusted profit outlook based on “tariffs and geopolitical conditions”, said Chief Financial Officer Karleen Oberton.
The company expects a profit of $4.15 to $4.25 per share for fiscal 2025, compared with its previous forecast of $4.25 to $4.35 per share. Analysts expect a profit of $4.26 per share for fiscal 2025, according to data compiled by LSEG.
“When we analyze the tariffs that have been announced relative to our manufacturing activities, we forecast a gross impact of $20 to $25 million a quarter,” said Chief Operating Officer Essex Mitchell in a conference call.
Hologix expects its third-quarter adjusted profit per share to be between $1.04 and $1.07, which is lower than estimates of $1.10 per share.
The company’s breast health segment revenue for the second quarter fell 7.4% to $356.2 million, reflecting lower sales of mammography capital equipment.
Hologic had previously warned that the demand for gantry placements, medical equipment used in medical imaging and radiation therapy, would be lower in 2025, although it expects the segment to return to healthy growth in the fourth quarter.
Hologic also reaffirmed its annual sales forecast for fiscal 2025 to range between $4.05 billion and $4.1 billion.
The company’s total revenue for the three months ended March 30 was in line with estimates.
On an adjusted basis, Hologic reported a profit of $1.03 per share, slightly above analysts’ estimates of $1.02 per share for the second quarter.
(Reporting by Sruthi Narasimha Chari in Bengaluru; Editing by Mohammed Safi Shamsi)
Comments